Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
Cingulate Inc. (CING)
Company Research
Source: GlobeNewswire
KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, and preeminent board-certified psychiatrist and Cingulate scientific advisor Dr. Ann Childress, MD, will participate in a live Benzinga All Access event on June 26, 2024, at 10:30 a.m. CST. The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), a review of the results from Cingulate’s Phase 3 Fixed-Dose Study in pediatrics and adolescents, and the potential expansion of Cingulate’s PTR platform into other therapeutic areas. Dr. Schaffer will also provide a company overview. The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on
Show less
Read more
Impact Snapshot
Event Time:
CING
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CING alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CING alerts
High impacting Cingulate Inc. news events
Weekly update
A roundup of the hottest topics
CING
News
- Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301GlobeNewswire
- Cingulate to Participate in Benzinga All Live Access EventGlobeNewswire
- Cingulate Announces Adjournment of Special MeetingGlobeNewswire
- Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones AchievedGlobeNewswire
- Collegium buys Ironshore for $525m and enter ADHD market [Yahoo! Finance]Yahoo! Finance
CING
Sec Filings
- 9/27/24 - Form S-1
- 9/12/24 - Form 8-K
- 9/10/24 - Form 8-K
- CING's page on the SEC website